ArticleJournal of managed care & specialty pharmacy2024
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States.
Sikander Ailawadhi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.